Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents. © Springer Science+Business Media, LLC 2010.
CITATION STYLE
Coriat, R., Ropert, S., Mir, O., Billemont, B., Chaussade, S., Massault, P. P., … Goldwasser, F. (2011). Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Investigational New Drugs, 29(5), 1090–1093. https://doi.org/10.1007/s10637-010-9458-7
Mendeley helps you to discover research relevant for your work.